Although suggestive, these data are very preliminary, and further studies are warranted to validate a role of BRD4 in PRMT5 overexpression in CLL/RT, and to resolve the numerous trans interactions of unexplored significance, where irregular activity at any number of these locations may play a significant role in promoting PRMT5 expression. The gene discussed is BRD4; the disease is B-cell chronic lymphocytic leukemia.